Delivery Order SPE2DB24D2010-SPE2DB25FAAPP
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $34,841.13 on May 30, 2025, for the supply of Multaq 400 mg tablets (60-count units) to support federal medical procurement needs. This firm fixed-price, competitively awarded contract (no set-aside designation) is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 2, 2025. The delivery order is funded through the Defense Medical Supply Chain, a...
- The Defense Logistics Agency awarded a delivery order valued at $6,351.04 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 17, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $1,025.26. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 18, 2025, and performance based in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on May 6, 2025, for $5,578.34 to supply 60 tablets of Multaq 400 mg, a pharmaceutical product used in cardiovascular treatment. This is a firm fixed price, non-competitive delivery order executed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $22,459.46 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Multaq 400 mg tablets (60-count units). This is a firm fixed-price contract with an ultimate completion date of August 14, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- This federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Multaq 400 mg tablets. The $18,267.20 firm fixed-price delivery order has an ultimate completion date of October 26, 2023 and was awarded on October 25, 2023. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency on August 4, 2025, for the supply of Multaq 400 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $6.2K. The contract is non-set-aside and competitively awarded, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $9,432.60 delivery order to AmerisourceBergen Drug Corp on April 28, 2025, for the supply of Multaq 400 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of April 29, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $21,298.99 firm-fixed-price delivery order is for the supply of Multaq 400 mg tablets. The contract has a period of performance through May 9, 2025 and is not set aside. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count) valued at $7,313.70 under a firm fixed price contract. The award was made on August 21, 2025, with an ultimate completion date of August 22, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen will perform this delivery order from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAAPPDelivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order valued at $39,232.30 by the Defense Logistics Agency (DLA) for the supply of Multaq 400 mg tablets (60-count units). This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by July 31, 2025. The award was issued on July 30, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's ongoing pharmaceutical supply relationship with the federal government's medical procurement systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 and extends through December 2026. This comprehensive global pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs and other federal health systems worldwide. The company's role as a primary pharmaceutical distributor for the Defense Health Agency and other government healthcare entities reflects its significance within the federal medical supply chain, particularly for delivering brand-name and generic medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $39.2k | 7/30/25 |